APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immune Checkpoint Agents

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Immune Checkpoint Agents Market Analysis and Forecast 2026-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchImmune Checkpoint Agents Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Immune Checkpoint Agents Industry Growth and Trends Forecast to 203277 pages · $3,450 USDMarket StructureGlobal Immune Checkpoint Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immune Checkpoint Agents Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Immune Checkpoint Agents Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Immune Checkpoint Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Immune Checkpoint Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Immune Checkpoint Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Immune Checkpoint Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Immune Checkpoint Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Immune Checkpoint Agents include Bristol Myers Squibb, AstraZeneca, Roche and Merck, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Immune Checkpoint Agents, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Immune Checkpoint Agents, also provides the sales of main regions and countries. Of the upcoming market potential for Immune Checkpoint Agents, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Immune Checkpoint Agents sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Immune Checkpoint Agents market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Immune Checkpoint Agents sales, projected growth trends, production technology, application and end-user industry.

Immune Checkpoint Agents Segment by Company

Bristol Myers Squibb

AstraZeneca

Roche

Merck

Immune Checkpoint Agents Segment by Type

Anti-PD-L1 Drug

Anti-PD-1 Drug

CTLA4

Immune Checkpoint Agents Segment by Application

Lung Cancer

Melanoma

Colorectal Cancer

Prostate Cancer

BreastCancer

Blood Cancers

Immune Checkpoint Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Checkpoint Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immune Checkpoint Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Checkpoint Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Immune Checkpoint Agents in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Immune Checkpoint Agents manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immune Checkpoint Agents sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immune Checkpoint Agents Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Anti-PD-L1 Drug Major Manufacturers Table 3. Anti-PD-1 Drug Major Manufacturers Table 4. CTLA4 Major Manufacturers Table 5. Global Immune Checkpoint Agents Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Lung Cancer Major Manufacturers Table 7. Melanoma Major Manufacturers Table 8. Colorectal Cancer Major Manufacturers Table 9. Prostate Cancer Major Manufacturers Table 10. BreastCancer Major Manufacturers Table 11. Blood Cancers Major Manufacturers Table 12. Immune Checkpoint Agents Industry Trends Table 13. Immune Checkpoint Agents Industry Drivers Table 14. Immune Checkpoint Agents Industry Opportunities and Challenges Table 15. Immune Checkpoint Agents Industry Restraints Table 16. Global Immune Checkpoint Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Immune Checkpoint Agents Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Immune Checkpoint Agents Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Immune Checkpoint Agents Revenue Market Share by Region (2021-2026) Table 20. Global Immune Checkpoint Agents Revenue Market Share by Region (2027-2032) Table 21. Global Immune Checkpoint Agents Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Immune Checkpoint Agents Sales by Region (2021-2026) & (K Units) Table 23. Global Immune Checkpoint Agents Sales by Region (2027-2032) & (K Units) Table 24. Global Immune Checkpoint Agents Sales Market Share by Region (2021-2026) Table 25. Global Immune Checkpoint Agents Sales Market Share by Region (2027-2032) Table 26. Global Immune Checkpoint Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Immune Checkpoint Agents Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Immune Checkpoint Agents Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Immune Checkpoint Agents Sales Market Share by Manufacturers (2021-2026) Table 30. Global Immune Checkpoint Agents Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Immune Checkpoint Agents Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Immune Checkpoint Agents Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Immune Checkpoint Agents Manufacturers, Product Type & Application Table 34. Global Immune Checkpoint Agents Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Immune Checkpoint Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Immune Checkpoint Agents Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Immune Checkpoint Agents Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Immune Checkpoint Agents Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Immune Checkpoint Agents Revenue Market Share by Type (2021-2026) Table 41. Global Immune Checkpoint Agents Revenue Market Share by Type (2027-2032) Table 42. Global Immune Checkpoint Agents Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 44. Global Immune Checkpoint Agents Sales by Type (2027-2032) & (K Units) Table 45. Global Immune Checkpoint Agents Sales Market Share by Type (2021-2026) Table 46. Global Immune Checkpoint Agents Sales Market Share by Type (2027-2032) Table 47. Global Immune Checkpoint Agents Price by Type (2021-2026) & (US$/Unit) Table 48. Global Immune Checkpoint Agents Price by Type (2027-2032) & (US$/Unit) Table 49. Global Immune Checkpoint Agents Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Immune Checkpoint Agents Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Immune Checkpoint Agents Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Immune Checkpoint Agents Revenue Market Share by Application (2021-2026) Table 53. Global Immune Checkpoint Agents Revenue Market Share by Application (2027-2032) Table 54. Global Immune Checkpoint Agents Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 56. Global Immune Checkpoint Agents Sales by Application (2027-2032) & (K Units) Table 57. Global Immune Checkpoint Agents Sales Market Share by Application (2021-2026) Table 58. Global Immune Checkpoint Agents Sales Market Share by Application (2027-2032) Table 59. Global Immune Checkpoint Agents Price by Application (2021-2026) & (US$/Unit) Table 60. Global Immune Checkpoint Agents Price by Application (2027-2032) & (US$/Unit) Table 61. Bristol Myers Squibb Company Information Table 62. Bristol Myers Squibb Business Overview Table 63. Bristol Myers Squibb Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Bristol Myers Squibb Immune Checkpoint Agents Product Portfolio Table 65. Bristol Myers Squibb Recent Development Table 66. AstraZeneca Company Information Table 67. AstraZeneca Business Overview Table 68. AstraZeneca Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. AstraZeneca Immune Checkpoint Agents Product Portfolio Table 70. AstraZeneca Recent Development Table 71. Roche Company Information Table 72. Roche Business Overview Table 73. Roche Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Roche Immune Checkpoint Agents Product Portfolio Table 75. Roche Recent Development Table 76. Merck Company Information Table 77. Merck Business Overview Table 78. Merck Immune Checkpoint Agents Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Merck Immune Checkpoint Agents Product Portfolio Table 80. Merck Recent Development Table 81. North America Immune Checkpoint Agents Revenue by Type (2021-2026) & (US$ Million) Table 82. North America Immune Checkpoint Agents Revenue by Type (2027-2032) & (US$ Million) Table 83. North America Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 84. North America Immune Checkpoint Agents Sales by Type (2027-2032) & (K Units) Table 85. North America Immune Checkpoint Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 86. North America Immune Checkpoint Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 87. North America Immune Checkpoint Agents Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Immune Checkpoint Agents Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 90. North America Immune Checkpoint Agents Sales by Application (2027-2032) & (K Units) Table 91. North America Immune Checkpoint Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 92. North America Immune Checkpoint Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 93. North America Immune Checkpoint Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. North America Immune Checkpoint Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 95. North America Immune Checkpoint Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 96. North America Immune Checkpoint Agents Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 97. North America Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 98. North America Immune Checkpoint Agents Sales by Country (2027-2032) & (K Units) Table 99. North America Immune Checkpoint Agents Sales Price by Country (2021-2026) & (US$/Unit) Table 100. North America Immune Checkpoint Agents Sales Price by Country (2027-2032) & (US$/Unit) Table 101. United States Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 102. Canada Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 103. Mexico Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 104. Europe Immune Checkpoint Agents Revenue by Type (2021-2026) & (US$ Million) Table 105. Europe Immune Checkpoint Agents Revenue by Type (2027-2032) & (US$ Million) Table 106. Europe Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 107. Europe Immune Checkpoint Agents Sales by Type (2027-2032) & (K Units) Table 108. Europe Immune Checkpoint Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 109. Europe Immune Checkpoint Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 110. Europe Immune Checkpoint Agents Revenue by Application (2021-2026) & (US$ Million) Table 111. Europe Immune Checkpoint Agents Revenue by Application (2027-2032) & (US$ Million) Table 112. Europe Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 113. Europe Immune Checkpoint Agents Sales by Application (2027-2032) & (K Units) Table 114. Europe Immune Checkpoint Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 115. Europe Immune Checkpoint Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 116. Europe Immune Checkpoint Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Immune Checkpoint Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 118. Europe Immune Checkpoint Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 119. Europe Immune Checkpoint Agents Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 120. Europe Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 121. Europe Immune Checkpoint Agents Sales by Country (2027-2032) & (K Units) Table 122. Europe Immune Checkpoint Agents Sales Price by Country (2021-2026) & (US$/Unit) Table 123. Europe Immune Checkpoint Agents Sales Price by Country (2027-2032) & (US$/Unit) Table 124. Germany Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 125. France Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 126. U.K. Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 127. Italy Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 128. Russia Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 129. Spain Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 130. Netherlands Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 131. Switzerland Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 132. Sweden Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 133. Poland Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 134. China Immune Checkpoint Agents Revenue by Type (2021-2026) & (US$ Million) Table 135. China Immune Checkpoint Agents Revenue by Type (2027-2032) & (US$ Million) Table 136. China Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 137. China Immune Checkpoint Agents Sales by Type (2027-2032) & (K Units) Table 138. China Immune Checkpoint Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 139. China Immune Checkpoint Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 140. China Immune Checkpoint Agents Revenue by Application (2021-2026) & (US$ Million) Table 141. China Immune Checkpoint Agents Revenue by Application (2027-2032) & (US$ Million) Table 142. China Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 143. China Immune Checkpoint Agents Sales by Application (2027-2032) & (K Units) Table 144. China Immune Checkpoint Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 145. China Immune Checkpoint Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 146. Asia Immune Checkpoint Agents Revenue by Type (2021-2026) & (US$ Million) Table 147. Asia Immune Checkpoint Agents Revenue by Type (2027-2032) & (US$ Million) Table 148. Asia Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 149. Asia Immune Checkpoint Agents Sales by Type (2027-2032) & (K Units) Table 150. Asia Immune Checkpoint Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 151. Asia Immune Checkpoint Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 152. Asia Immune Checkpoint Agents Revenue by Application (2021-2026) & (US$ Million) Table 153. Asia Immune Checkpoint Agents Revenue by Application (2027-2032) & (US$ Million) Table 154. Asia Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 155. Asia Immune Checkpoint Agents Sales by Application (2027-2032) & (K Units) Table 156. Asia Immune Checkpoint Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 157. Asia Immune Checkpoint Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 158. Asia Immune Checkpoint Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Asia Immune Checkpoint Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. Asia Immune Checkpoint Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. Asia Immune Checkpoint Agents Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 162. Asia Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 163. Asia Immune Checkpoint Agents Sales by Country (2027-2032) & (K Units) Table 164. Asia Immune Checkpoint Agents Sales Price by Country (2021-2026) & (US$/Unit) Table 165. Asia Immune Checkpoint Agents Sales Price by Country (2027-2032) & (US$/Unit) Table 166. Japan Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 167. South Korea Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 168. India Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 169. Australia Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 170. Taiwan Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 171. Southeast Asia Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 172. SAMEA Immune Checkpoint Agents Revenue by Type (2021-2026) & (US$ Million) Table 173. SAMEA Immune Checkpoint Agents Revenue by Type (2027-2032) & (US$ Million) Table 174. SAMEA Immune Checkpoint Agents Sales by Type (2021-2026) & (K Units) Table 175. SAMEA Immune Checkpoint Agents Sales by Type (2027-2032) & (K Units) Table 176. SAMEA Immune Checkpoint Agents Sales Price by Type (2021-2026) & (US$/Unit) Table 177. SAMEA Immune Checkpoint Agents Sales Price by Type (2027-2032) & (US$/Unit) Table 178. SAMEA Immune Checkpoint Agents Revenue by Application (2021-2026) & (US$ Million) Table 179. SAMEA Immune Checkpoint Agents Revenue by Application (2027-2032) & (US$ Million) Table 180. SAMEA Immune Checkpoint Agents Sales by Application (2021-2026) & (K Units) Table 181. SAMEA Immune Checkpoint Agents Sales by Application (2027-2032) & (K Units) Table 182. SAMEA Immune Checkpoint Agents Sales Price by Application (2021-2026) & (US$/Unit) Table 183. SAMEA Immune Checkpoint Agents Sales Price by Application (2027-2032) & (US$/Unit) Table 184. SAMEA Immune Checkpoint Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. SAMEA Immune Checkpoint Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. SAMEA Immune Checkpoint Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. SAMEA Immune Checkpoint Agents Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 188. SAMEA Immune Checkpoint Agents Sales by Country (2021-2026) & (K Units) Table 189. SAMEA Immune Checkpoint Agents Sales by Country (2027-2032) & (K Units) Table 190. SAMEA Immune Checkpoint Agents Sales Price by Country (2021-2026) & (US$/Unit) Table 191. SAMEA Immune Checkpoint Agents Sales Price by Country (2027-2032) & (US$/Unit) Table 192. Brazil Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 193. Argentina Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 194. Chile Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 195. Colombia Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 196. Peru Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 197. Saudi Arabia Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 198. Israel Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 199. UAE Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 200. Turkey Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 201. Iran Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 202. Egypt Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Table 203. Key Raw Materials Table 204. Raw Materials Key Suppliers Table 205. Immune Checkpoint Agents Distributors List Table 206. Immune Checkpoint Agents Customers List Table 207. Research Programs/Design for This Report Table 208. Authors List of This Report Table 209. Secondary Sources Table 210. Primary Sources List of Figures Figure 1. Immune Checkpoint Agents Image Figure 2. Global Immune Checkpoint Agents Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immune Checkpoint Agents Market Size Share 2021 VS 2025 VS 2032 Figure 4. Anti-PD-L1 Drug Image Figure 5. Anti-PD-1 Drug Image Figure 6. CTLA4 Image Figure 7. Global Immune Checkpoint Agents Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Immune Checkpoint Agents Market Size Share 2021 VS 2025 VS 2032 Figure 9. Lung Cancer Image Figure 10. Melanoma Image Figure 11. Colorectal Cancer Image Figure 12. Prostate Cancer Image Figure 13. BreastCancer Image Figure 14. Blood Cancers Image Figure 15. Global Immune Checkpoint Agents Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Immune Checkpoint Agents Revenue (2021-2032) & (US$ Million) Figure 17. Global Immune Checkpoint Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Immune Checkpoint Agents Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Immune Checkpoint Agents Revenue Market Share by Region (2021-2032) Figure 20. Global Immune Checkpoint Agents Sales (2021-2032) & (K Units) Figure 21. Global Immune Checkpoint Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Immune Checkpoint Agents Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Immune Checkpoint Agents Sales YoY (2021-2032) & (K Units) Figure 24. Europe Immune Checkpoint Agents Sales YoY (2021-2032) & (K Units) Figure 25. China Immune Checkpoint Agents Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Immune Checkpoint Agents Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Immune Checkpoint Agents Sales YoY (2021-2032) & (K Units) Figure 28. Global Immune Checkpoint Agents Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Immune Checkpoint Agents Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Immune Checkpoint Agents Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Immune Checkpoint Agents Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Immune Checkpoint Agents Revenue Market Share by Type (2021-2032) Figure 34. Global Immune Checkpoint Agents Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Immune Checkpoint Agents Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Immune Checkpoint Agents Sales Market Share by Type (2021-2032) Figure 37. Global Immune Checkpoint Agents Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Immune Checkpoint Agents Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Immune Checkpoint Agents Revenue Market Share by Application (2021-2032) Figure 40. Global Immune Checkpoint Agents Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Immune Checkpoint Agents Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Immune Checkpoint Agents Sales Market Share by Application (2021-2032) Figure 43. North America Immune Checkpoint Agents Revenue Share by Type (2021-2032) Figure 44. North America Immune Checkpoint Agents Sales Share by Type (2021-2032) Figure 45. North America Immune Checkpoint Agents Revenue Share by Application (2021-2032) Figure 46. North America Immune Checkpoint Agents Sales Share by Application (2021-2032) Figure 47. North America Immune Checkpoint Agents Revenue Share by Country (2021-2032) Figure 48. North America Immune Checkpoint Agents Sales Share by Country (2021-2032) Figure 49. Europe Immune Checkpoint Agents Revenue Share by Type (2021-2032) Figure 50. Europe Immune Checkpoint Agents Sales Share by Type (2021-2032) Figure 51. Europe Immune Checkpoint Agents Revenue Share by Application (2021-2032) Figure 52. Europe Immune Checkpoint Agents Sales Share by Application (2021-2032) Figure 53. Europe Immune Checkpoint Agents Revenue Share by Country (2021-2032) Figure 54. Europe Immune Checkpoint Agents Sales Share by Country (2021-2032) Figure 55. China Immune Checkpoint Agents Revenue Share by Type (2021-2032) Figure 56. China Immune Checkpoint Agents Sales Share by Type (2021-2032) Figure 57. China Immune Checkpoint Agents Revenue Share by Application (2021-2032) Figure 58. China Immune Checkpoint Agents Sales Share by Application (2021-2032) Figure 59. Asia Immune Checkpoint Agents Revenue Share by Type (2021-2032) Figure 60. Asia Immune Checkpoint Agents Sales Share by Type (2021-2032) Figure 61. Asia Immune Checkpoint Agents Revenue Share by Application (2021-2032) Figure 62. Asia Immune Checkpoint Agents Sales Share by Application (2021-2032) Figure 63. Asia Immune Checkpoint Agents Revenue Share by Country (2021-2032) Figure 64. Asia Immune Checkpoint Agents Sales Share by Country (2021-2032) Figure 65. SAMEA Immune Checkpoint Agents Revenue Share by Type (2021-2032) Figure 66. SAMEA Immune Checkpoint Agents Sales Share by Type (2021-2032) Figure 67. SAMEA Immune Checkpoint Agents Revenue Share by Application (2021-2032) Figure 68. SAMEA Immune Checkpoint Agents Sales Share by Application (2021-2032) Figure 69. SAMEA Immune Checkpoint Agents Revenue Share by Country (2021-2032) Figure 70. SAMEA Immune Checkpoint Agents Sales Share by Country (2021-2032) Figure 71. Immune Checkpoint Agents Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Immune Checkpoint Agents Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-PD-L1 Drug
  • Anti-PD-1 Drug
  • CTLA4
Applications
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Prostate Cancer
  • BreastCancer
  • Blood Cancers
Companies covered
  • Bristol Myers Squibb
  • AstraZeneca
  • Roche
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Immune Checkpoint Agents Market by Type
  3. 1.2.1 Global Immune Checkpoint Agents Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Anti-PD-L1 Drug
  5. 1.2.3 Anti-PD-1 Drug
  6. 1.2.4 CTLA4
  7. 1.3 Immune Checkpoint Agents Market by Application
  8. 1.3.1 Global Immune Checkpoint Agents Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Lung Cancer
  10. 1.3.3 Melanoma
  11. 1.3.4 Colorectal Cancer
  12. 1.3.5 Prostate Cancer
  13. 1.3.6 BreastCancer
  14. 1.3.7 Blood Cancers
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Immune Checkpoint Agents Market Dynamics
  1. 2.1 Immune Checkpoint Agents Industry Trends
  2. 2.2 Immune Checkpoint Agents Industry Drivers
  3. 2.3 Immune Checkpoint Agents Industry Opportunities and Challenges
  4. 2.4 Immune Checkpoint Agents Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Immune Checkpoint Agents Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Immune Checkpoint Agents Revenue by Region
  3. 3.2.1 Global Immune Checkpoint Agents Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Immune Checkpoint Agents Revenue by Region (2021-2026)
  5. 3.2.3 Global Immune Checkpoint Agents Revenue by Region (2027-2032)
  6. 3.2.4 Global Immune Checkpoint Agents Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Immune Checkpoint Agents Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Immune Checkpoint Agents Sales by Region
  9. 3.4.1 Global Immune Checkpoint Agents Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Immune Checkpoint Agents Sales by Region (2021-2026)
  11. 3.4.3 Global Immune Checkpoint Agents Sales by Region (2027-2032)
  12. 3.4.4 Global Immune Checkpoint Agents Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Immune Checkpoint Agents Revenue by Manufacturers
  2. 4.1.1 Global Immune Checkpoint Agents Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Immune Checkpoint Agents Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Immune Checkpoint Agents Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Immune Checkpoint Agents Sales by Manufacturers
  6. 4.2.1 Global Immune Checkpoint Agents Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Immune Checkpoint Agents Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Immune Checkpoint Agents Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Immune Checkpoint Agents Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Immune Checkpoint Agents Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Immune Checkpoint Agents Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Immune Checkpoint Agents Manufacturers, Product Type & Application
  13. 4.7 Global Immune Checkpoint Agents Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Immune Checkpoint Agents Market CR5 and HHI
  16. 4.8.2 2025 Immune Checkpoint Agents Tier 1, Tier 2, and Tier 3
5 Immune Checkpoint Agents Market by Type
  1. 5.1 Global Immune Checkpoint Agents Revenue by Type
  2. 5.1.1 Global Immune Checkpoint Agents Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Immune Checkpoint Agents Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Immune Checkpoint Agents Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Immune Checkpoint Agents Sales by Type
  6. 5.2.1 Global Immune Checkpoint Agents Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Immune Checkpoint Agents Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Immune Checkpoint Agents Sales Market Share by Type (2021-2032)
  9. 5.3 Global Immune Checkpoint Agents Price by Type
6 Immune Checkpoint Agents Market by Application
  1. 6.1 Global Immune Checkpoint Agents Revenue by Application
  2. 6.1.1 Global Immune Checkpoint Agents Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Immune Checkpoint Agents Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Immune Checkpoint Agents Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Immune Checkpoint Agents Sales by Application
  6. 6.2.1 Global Immune Checkpoint Agents Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Immune Checkpoint Agents Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Immune Checkpoint Agents Sales Market Share by Application (2021-2032)
  9. 6.3 Global Immune Checkpoint Agents Price by Application
7 Company Profiles
  1. 7.1 Bristol Myers Squibb
  2. 7.1.1 Bristol Myers Squibb Company Information
  3. 7.1.2 Bristol Myers Squibb Business Overview
  4. 7.1.3 Bristol Myers Squibb Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bristol Myers Squibb Immune Checkpoint Agents Product Portfolio
  6. 7.1.5 Bristol Myers Squibb Recent Developments
  7. 7.2 AstraZeneca
  8. 7.2.1 AstraZeneca Company Information
  9. 7.2.2 AstraZeneca Business Overview
  10. 7.2.3 AstraZeneca Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 AstraZeneca Immune Checkpoint Agents Product Portfolio
  12. 7.2.5 AstraZeneca Recent Developments
  13. 7.3 Roche
  14. 7.3.1 Roche Company Information
  15. 7.3.2 Roche Business Overview
  16. 7.3.3 Roche Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Roche Immune Checkpoint Agents Product Portfolio
  18. 7.3.5 Roche Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Immune Checkpoint Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck Immune Checkpoint Agents Product Portfolio
  24. 7.4.5 Merck Recent Developments
8 North America
  1. 8.1 North America Immune Checkpoint Agents Market Size by Type
  2. 8.1.1 North America Immune Checkpoint Agents Revenue by Type (2021-2032)
  3. 8.1.2 North America Immune Checkpoint Agents Sales by Type (2021-2032)
  4. 8.1.3 North America Immune Checkpoint Agents Price by Type (2021-2032)
  5. 8.2 North America Immune Checkpoint Agents Market Size by Application
  6. 8.2.1 North America Immune Checkpoint Agents Revenue by Application (2021-2032)
  7. 8.2.2 North America Immune Checkpoint Agents Sales by Application (2021-2032)
  8. 8.2.3 North America Immune Checkpoint Agents Price by Application (2021-2032)
  9. 8.3 North America Immune Checkpoint Agents Market Size by Country
  10. 8.3.1 North America Immune Checkpoint Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Immune Checkpoint Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Immune Checkpoint Agents Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Immune Checkpoint Agents Market Size by Type
  2. 9.1.1 Europe Immune Checkpoint Agents Revenue by Type (2021-2032)
  3. 9.1.2 Europe Immune Checkpoint Agents Sales by Type (2021-2032)
  4. 9.1.3 Europe Immune Checkpoint Agents Price by Type (2021-2032)
  5. 9.2 Europe Immune Checkpoint Agents Market Size by Application
  6. 9.2.1 Europe Immune Checkpoint Agents Revenue by Application (2021-2032)
  7. 9.2.2 Europe Immune Checkpoint Agents Sales by Application (2021-2032)
  8. 9.2.3 Europe Immune Checkpoint Agents Price by Application (2021-2032)
  9. 9.3 Europe Immune Checkpoint Agents Market Size by Country
  10. 9.3.1 Europe Immune Checkpoint Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Immune Checkpoint Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Immune Checkpoint Agents Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Immune Checkpoint Agents Market Size by Type
  2. 10.1.1 China Immune Checkpoint Agents Revenue by Type (2021-2032)
  3. 10.1.2 China Immune Checkpoint Agents Sales by Type (2021-2032)
  4. 10.1.3 China Immune Checkpoint Agents Price by Type (2021-2032)
  5. 10.2 China Immune Checkpoint Agents Market Size by Application
  6. 10.2.1 China Immune Checkpoint Agents Revenue by Application (2021-2032)
  7. 10.2.2 China Immune Checkpoint Agents Sales by Application (2021-2032)
  8. 10.2.3 China Immune Checkpoint Agents Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Immune Checkpoint Agents Market Size by Type
  2. 11.1.1 Asia Immune Checkpoint Agents Revenue by Type (2021-2032)
  3. 11.1.2 Asia Immune Checkpoint Agents Sales by Type (2021-2032)
  4. 11.1.3 Asia Immune Checkpoint Agents Price by Type (2021-2032)
  5. 11.2 Asia Immune Checkpoint Agents Market Size by Application
  6. 11.2.1 Asia Immune Checkpoint Agents Revenue by Application (2021-2032)
  7. 11.2.2 Asia Immune Checkpoint Agents Sales by Application (2021-2032)
  8. 11.2.3 Asia Immune Checkpoint Agents Price by Application (2021-2032)
  9. 11.3 Asia Immune Checkpoint Agents Market Size by Country
  10. 11.3.1 Asia Immune Checkpoint Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Immune Checkpoint Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Immune Checkpoint Agents Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Immune Checkpoint Agents Market Size by Type
  2. 12.1.1 SAMEA Immune Checkpoint Agents Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Immune Checkpoint Agents Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Immune Checkpoint Agents Price by Type (2021-2032)
  5. 12.2 SAMEA Immune Checkpoint Agents Market Size by Application
  6. 12.2.1 SAMEA Immune Checkpoint Agents Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Immune Checkpoint Agents Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Immune Checkpoint Agents Price by Application (2021-2032)
  9. 12.3 SAMEA Immune Checkpoint Agents Market Size by Country
  10. 12.3.1 SAMEA Immune Checkpoint Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Immune Checkpoint Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Immune Checkpoint Agents Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Immune Checkpoint Agents Value Chain Analysis
  2. 13.1.1 Immune Checkpoint Agents Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Immune Checkpoint Agents Production Mode & Process
  6. 13.2 Immune Checkpoint Agents Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Immune Checkpoint Agents Distributors
  9. 13.2.3 Immune Checkpoint Agents Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst